Overexpression of vascular endothelin-1 and endothelin-A receptors in a fructose-induced hypertensive rat model

Journal of Hypertension

Volumn 16, Issue 12, 1998, Pages 1775-1782

  Juan, Chi Chang ^a,b   Fang, Victor S ^b   Hsu, Yung Pei ^b   Huang, Yan Jiun ^a   Hsia, Ding Bung ^a   Yu, Pi Chin ^a,b   Kwok, Ching Fai ^b   Ho, Low Tone ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

BQ 610; Endothelin 1; Endothelin A receptor; Fructose; Hyperinsulinemia; Hypertension

Indexed keywords

BQ 610; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; FRUCTOSE; INSULIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; GENE EXPRESSION; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC HYPERTENSION;

EID: 0031793607     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816120-00010     Document Type: Article

References (49)

1. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75:809-817.
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.
3. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lower blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320.
4. Hwang I-S, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10:512-516.
5. Verma S, Bhanot S, McNeill JH. Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats. J Pharmacol Erp Ther 1994; 271:1334-1337.
6. Lee M-K, Miles P.D, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994; 43:1435-1439.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, el al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
8. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992; 13:103-108.
9. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
10. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
11. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797-9800.
12. Goetz KL, Wang BC, Madwed JB, Zhu JL, Leadley RJ. Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol 1988; 255:R1064-R1068.
13. Spokes RA, Ghatei MA, Bloom SR. Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissue: evidence for multiple endothelin receptor subtypes. J Cardiovasc Pharmcol 1989; 13(suppl 5):S191-S192.
14. Kohno M, Yasumari K, Murakawa K, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
15. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
16. Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T, et al. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun 1990; 167:941-947.
17. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
18. Lariviere R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21:916-920.
19. Schiffrin EL, Lariviere R, Li J-S, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25:769-773.
20. Hasegawa K, Fujiwara H, Doyama K, Inada T, Ohtani S, Fujiwara T, et al. Endothelin-1-selective receptor in the arterial intima of patients with hypertension. Hypertension 1994; 23:288-293.
21. Hu R-M, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42:351-358.
22. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 1993; 42:1027-1030.
23. Frank HJ, Levin ER, Hu R-M, Pedram A. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology 1993; 133:1092-1097.
24. Ferri C, Bellini C, Desideri G, Baldoncini R, De Siati L, Santucci A. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities. Diabetologia 1997; 40:100-102.
25. Chou YC, Perng JC, Juan CC, Jang SY, Kowk CF, Chen WL, et al. Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes. Biochem Biophys Res Commun 1994; 202:688-693.
26. Juan C-C, Fang VS, Huang Y-J, Kwok C-F, Hsu Y-P, Ho LT. Endothelin-1 induces insulin resistance in conscious rats. Biochem Biophys Res Commun 1996; 227:694-699.
27. Bunag RD, Butterfield J. Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension 1982; 4:898-903.
28. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973; 34:279-282.
29. Maeso R, Navarro-Cid J, Munoz-Garcia R, Rodrigo E, Ruilope LM, Lahera V, et al. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats: role of nitric oxide and angiotensin II type 2 receptors. Hypertension 1996; 28:967-972.
30. Davis LG, Kuehl WM, Battey JF. Formaldehyde agarose gel electrophoresis and RNA (Northern) blots. In: Basic methods in molecular biology, 2nd ed. Norwalk, Connecticut: Appleton and Lange; 1994. pp. 350-354.
31. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132:6-13.
32. Ho LT, Pu HF, Sheu WJ, Wang WC, Wang PS. Inhibition of somatostatin on glucose-induced release of gastric inhibitory polypeptide in rats. Chin J Physiol 1987; 30:45-53.
33. Xuan YT, Whorton AR, Shearer-Poor E, Boyd J, Watkins WD. Determination of immunoreactive endothelin in medium from cultured endothelial cells and human plasma. Biochem Biophys Res Commun 1989; 164:326-332.
34. Jenkins DJA, Wolever TMS, Taylor RH, Barker H, Fielden H, Baldwin JM, et al. Glycemic index of foods. a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34:362-366.
35. Wolever TMS, Miller JB. Sugars and blood glucose control. Am J Clin Nutr 1995; 62 (suppl 1):212S-227S.
36. Garvey WT, Olefsky JM, Marshall S. Insulin receptor down-regulation is linked to an insulin-induced postreceptor defect in the glucose transport system in rat adipocytes. J Clin Invest 1985; 76:22-30.
37. Anderson EA, Mark AL. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 1993; 21:136-141.
38. Axelrod L. Insulin, prostaglandins, and the pathogenesis of hypertension. Diabetes 1991; 40:1223-1227.
39. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267:16066-16068.
40. Lüscher TF. The endothelium as a target and mediator of cardiovascular disease. Eur J Clin Invest 1993; 23:670-685.
41. Verma S, Bhanot S, McNeill JH. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995; 269:H2017-H2021.
42. Yu JC, Davenport AP. Regulation of endothelin receptor expression in vascular smooth-muscle cells. J Cardiovasc Pharmcol 1995, 26 (suppl 3): S348-S350.
43. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 1993; 6:667-673.
44. Morishita R, Higaki J, Ogihara T. Endothelin stimulates aldosterone biosynthesis by dispersed rabbit adreno-capsular cells. Biochem Biophys Res Commun 1989; 160:628-632.
45. Boarder MR, Marriott DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989; 13 (suppl 5):S223-S224.
46. Yang ZH, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm. Circulation 1990; 82:188-195.
47. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78:225-228.
48. Miller WL, Redfield MM, Burnett JC. Integrated cardiovascular, renal, endocrine actions of endothelin. J Clin Invest 1989; 83:317-320.
49. Kaplan NM. Effects of hyperinsulinemia on blood pressure. In: Clinical hypertension, 6th ed. Baltimore: Williams and Wilkins; 1994. pp. 89-91.